Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2025-12-31

Summary

The purpose of this study is to explore the myeloprotective effects of trilaciclib in advanced squamous non-small cell lung cancer patients receiving a combination therapy of chemotherapy(carboplatin+paclitaxel) and immune checkpoint inhibitor (tislelizumab), as well as enhancing antitumor efficacy and possible immunological synergies.

• Phase: Phase 2

Details

• Lead Sponsor: Sichuan University
• Collaborators: Chengdu First people's hospital; Chengdu Second people's hospital; Chengdu Seventh People's Hospital; Enshi Central Hospital; Heilongjiang Provincial Cancer Hospital; Mianyang Central Hospital; Neijiang Hospital of Traditional Chinese Medicine; Shandong Provincial Cancer Hospital; Shanxi Provincial Cancer Hospital
• Treatments: Carboplatin; Paclitaxel; Tislelizumab